Table 1 Patients and tumours characteristics
PARP activity (Low < 7 U / mg Protein, High ≥ 7 U / mg Protein) | BRCA1methylation status | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Patients’ characteristics | N (%) | Low n (%) | High n (%) | p | Mean ± SD | p | Methylated n (%) | Not Methylated n (%) | p |
Age at diagnosis (years) | 0.92 | 0.83 | 0.17 | ||||||
Median (range) | 54 (29–75) | ||||||||
≤ 54 | 80 (51.6%) | 38 (52.1%) | 42 (51.2%) | 11.7 (13) | 12 (66.7%) | 68 (49.6%) | |||
> 54 | 75 (48.4%) | 35 (47.9%) | 40 (48.8%) | 12.7 (20.5) | 6 (33.3%) | 69 (50.4%) | |||
Menopausal status | 0.87 | 0.54 | 0.62 | ||||||
Pre-menopausal | 69 (44.5%) | 33 (45.2%) | 36 (43.9%) | 12.5 (13.8) | 9 (50.0%) | 60 (43.8%) | |||
Post-menopausal | 86 (55.5%) | 40 (54.8%) | 46 (56.1%) | 11.9 (19.3) | 9 (50.0%) | 77 (56.2%) | |||
T classification | 0.67 | 0.60 | 0.76 | ||||||
T1 | 76 (49%) | 36 (49.3%) | 40 (48.8%) | 14 (21.1) | 9 (50.0%) | 67 (48.9%) | |||
T2 | 75 (48.4%) | 36 (49.3%) | 39 (47.6%) | 10.4 (12) | 9 (50.0%) | 66 (48.2%) | |||
T3-4 | 4 (2.6%) | 1 (1.4%) | 3 (3.7%) | 10 (3.7) | 0 | 4 (2.9%) | |||
N classification | 0.75 | 0.8 | 0.71 | ||||||
N0 | 106 (68.4%) | 49 (67.1%) | 57 (69.5%) | 12.4 (18.1) | 13 (72.2%) | 93 (67.9%) | |||
N+ | 49 (31.6%) | 24 (32.9%) | 25 (30.5%) | 11.8 (14.6) | 5 (27.8%) | 44 (32.1%) | |||
Histology | 0.27 | 0.3 | 0.53 | ||||||
Ductal | 120 (77.4%) | 53 (72.6%) | 67 (81.7%) | 13.1 (18.3) | 15 (83.3%) | 105 (76.6%) | |||
Lobular | 9 (5.8%) | 4 (5.5%) | 5 (6.1%) | 7.8 (8.3) | 0 | 9 (6.6%) | |||
Other | 26 (16.8%) | 16 (21.9%) | 10 (12.2%) | 9.6 (12.5) | 3 (16.7%) | 23 (16.8%) | |||
Grade | 0.23 | 0.02 | 0.03 | ||||||
I / II | 1 (0.6%) / 51 (32.9%) | 28 (38.4%) | 24 (29.3%) | 9.2 (12.8) | 2 (11.1%) | 50 (36.5%) | |||
III | 103 (66.5%) | 45 (61.6%) | 58 (70.7%) | 13.7 (18.7) | 16 (88.9%) | 87 (63.5%) | |||
Mitotic count score | 0.04 | 0.003 | 0.04 | ||||||
1 | 31 (20%) | 20 (27.4%) | 11 (13.4%) | 8.3 (13.6) | 1 (5.6%) | 30 (21.9%) | |||
2 | 62 (40%) | 30 (41.1%) | 32 (39.0%) | 10.8 (16.2) | 5 (27.8%) | 57 (41.6%) | |||
3 | 62 (40%) | 23 (31.5%) | 39 (47.6%) | 15.6 (18.8) | 12 (66.7%) | 50 (36.5%) | |||
ER | 0.88 | 0.66 | 0.001 | ||||||
Positive | 88 (56.8%) | 41 (56.2%) | 47 (57.3%) | 12.1 (16.9) | 4 (22.2%) | 84 (61.3%) | |||
Negative | 67 (43.2%) | 32 (43.8%) | 35 (42.7%) | 12.4 (17.3) | 14 (77.8%) | 53 (38.7%) | |||
PR | 0.94 | 0.75 | 0.01 | ||||||
Positive | 59 (38.1%) | 28 (38.4%) | 31 (37.8%) | 11.5 (14.3) | 2 (11.1%) | 57 (41.6%) | |||
Negative | 96 (61.9%) | 45 (61.6%) | 51 (62.2%) | 12.6 (18.6) | 16 (88.9%) | 80 (58.4%) | |||
HER2 | 0.62 | 0.5 | 0.01 | ||||||
Positive | 50 (32.3%) | 25 (34.2%) | 25 (30.5%) | 9.7 (11.3) | 1 (5.6%) | 49 (35.8%) | |||
Negative | 105 (67.7%) | 48 (65.8%) | 57 (69.5%) | 13.4 (19.1) | 17 (94.4%) | 88 (64.2%) | |||
Molecular profile grouping | 0.81 | 0.68 | <0.001 | ||||||
HER2+ | 50 (32.3%) | 25 (34.2%) | 25 (30.5%) | 9.7 (11.3) | 1 (5.6%) | 49 (35.8%) | |||
HR+/HER2- | 57 (36.7%) | 25 (34.2%) | 32 (39.0%) | 13.4 (19.9) | 3 (16.7%) | 54 (39.4%) | |||
Triple negative | 48 (31%) | 23 (31.5%) | 25 (30.5%) | 13.4 (18.3) | 14 (77.8%) | 34 (24.8%) | |||
uPA level ( ≥3) | 0.37 | 0.3 | 0.01 | ||||||
High | 97 (62.6%) | 43 (58.9%) | 54 (65.9%) | 12.9 (17) | 16 (88.9%) | 81 (59.1%) | |||
Low | 58 (37.4%) | 30 (41.1%) | 28 (34.1%) | 11 (17.2) | 2 (11.1%) | 56 (40.9%) | |||
PAI-1 level ( ≥14) | 0.32 | 0.42 | 0.03 | ||||||
High | 112 (72.3%) | 50 (68.5%) | 62 (75.6%) | 11.4 (12.4) | 17 (94.4%) | 95 (69.3%) | |||
Low | 43 (27.7%) | 23 (31.5%) | 20 (24.4%) | 14.2 (25.5) | 1 (5.6%) | 42 (30.7%) | |||
PARP Activity | 0.82 | ||||||||
≤ 2.6 U/mg Prot | 39 (25.2%) | - | - | - | - | - | 4 (22.2%) | 35 (25.5%) | |
2.7 - 7 | 42 (27.1%) | - | - | - | - | - | 6 (33.3%) | 36 (26.3%) | |
7.1 - 14 | 37 (23.9%) | - | - | - | - | - | 3 (16.7%) | 34 (24.8%) | |
> 14 | 37 (23.9%) | - | - | - | - | - | 5 (27.8%) | 32 (23.4%) | |